Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Delcath Systems (DCTH) PT Raised to $20 at BTIG
August 6, 2024 4:57 AM EDTBTIG analyst Marie Thibault raised the price target on Delcath Systems (NASDAQ: DCTH) to $20.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "The U.S. commercial launch is ramping quicker than we initially expected with Delcath Systems reporting total Q2 sales of $7.8M, including $6.6M from Hepzato and $1.2M from OUS Chemosat sales. This was well above consensus of $5.2M. Seven treating centers were active in the quarter, performing what we estimate were 36 combined... More



